CRIS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRIS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Curis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.31 Mil. Curis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.49 Mil. Curis's annualized EBITDA for the quarter that ended in Dec. 2023 was $-36.79 Mil. Curis's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.08.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Curis's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of Curis was -0.01. The lowest was -1.91. And the median was -0.33.
The historical data trend for Curis's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.01 | -0.31 | -0.12 | -0.08 | -0.06 |
Curis Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.11 | -0.08 | -0.08 | -0.06 | -0.08 |
For the Biotechnology subindustry, Curis's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Curis's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Curis's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Curis's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (1.305 | + | 1.489) | / | -45.139 | |
= | -0.06 |
Curis's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (1.305 | + | 1.489) | / | -36.788 | |
= | -0.08 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.
Curis (NAS:CRIS) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Curis's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Jonathan B. Zung | officer: CDO | C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139 |
Anne Elizabeth Borgman | director | 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705 |
John Hohneker | director | C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139 |
Marc Rubin | director | C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080 |
Kenneth I Kaitin | director | C/O TUFTS CNTR FOR THE STUDY OF DRUG DEV, 75 KNEELAND ST, SUITE 1100, BOSTON MA 02111 |
Martyn D Greenacre | director | 41 MOORES ROAD, FRAZER PA 19355 |
Robert Martell | officer: Head of Research & Development | 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Diantha Duvall | officer: CFO | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
James E Dentzer | director, officer: President & CEO | C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
William Steinkrauss | officer: VP, Finance & Treasurer, other: Principal Accounting Officer | C/O CURIS, INC.,, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Lori Anne Kunkel | director | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Fattaey Ali Ph.d. | officer: President & COO | C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
James R Mcnab | director | C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Aurigene Discovery Technologies Ltd | 10 percent owner | 39-40 KIADB INDUSTRIAL AREA, PHASE II, ELECTRONIC CITY HOSUR ROAD, BANGALORE (KARNATAKA) K7 560100 |
David Tuck | officer: Sr. Vice-President | C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
From GuruFocus
By PRNewswire • 11-02-2023
By PRNewswire PRNewswire • 08-04-2022
By PRNewswire • 12-05-2023
By PRNewswire • 10-26-2023
By PRNewswire PRNewswire • 12-06-2022
By PRNewswire • 12-06-2023
By PRNewswire PRNewswire • 03-02-2023
By PRNewswire PRNewswire • 07-15-2022
By PRNewswire PRNewswire • 05-05-2023
By PRNewswire PRNewswire • 07-29-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.